Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

7.080 +0.380 (+5.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Via ACCESSWIRE
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Where NeoGenomics Stands With Analysts
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
4 Analysts Have This to Say About NeoGenomics
 
Via Benzinga
NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat
NeoGenomics, Inc. (NASDAQ: NEO) reported Q2 revenues of $146.92 million, +18% Y/Y, beating the  
Via Benzinga
NeoGenomics Reports Second Quarter 2023 Results
Via ACCESSWIRE
Earnings Scheduled For August 11, 2023
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. 
Via Benzinga
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Via ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
NeoGenomics's Return On Capital Employed Insights
 
Via Benzinga
NeoGenomics: Q1 Earnings Insights
 
Via Benzinga
NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares Soar
NeoGenomics Inc (NASDAQ: NEO) reported Q1 revenues of $137.22 mill 
Via Benzinga
Analyst Expectations for NeoGenomics's Future
 
Via Benzinga
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
NeoGenomics Reports First Quarter 2023 Results
Via ACCESSWIRE
What 9 Analyst Ratings Have To Say About NeoGenomics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
 
Via Benzinga
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
McKesson, ICU Medical, Novavax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
Via ACCESSWIRE
NeoGenomics, Inc. (NASDAQ:NEO) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/20/2023 -- An investigation concerning potential breaches of fiduciary duties by certain directors and officers of NeoGenomics, Inc was announced. 
Via SBWire
NeoGenomics to Announce First Quarter 2023 Financial Results
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.